Cargando…

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel

BACKGROUND: Immunotherapy (IO) has been associated with improved outcomes in patients with locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC). The primary objective of SPEAR‐Merkel was to explore treatment patterns, clinical outcomes, and health care resource...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhanegaonkar, Abhijeet, Liu, Frank X., Boyd, Marley, Fulcher, Nicole, Kim, Ruth, Krulewicz, Stan, Smith, Jodi, Cowey, C. Lance
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Melanoma and Cutaneous Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417847/ https://www.ncbi.nlm.nih.gov/pubmed/34101298 http://dx.doi.org/10.1002/onco.13845

Ejemplares similares

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective
por: Jung, Seungyeon, et al.
Publicado: (2022)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
por: Lacouture, Mario E., et al.
Publicado: (2016)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021)

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
por: Di Guardo, Lorenza, et al.
Publicado: (2021)

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
por: Kahana, Alon, et al.
Publicado: (2021)

Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
por: Anstadt, Emily J, et al.
Publicado: (2022)

Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020
por: Qian, Mollie F, et al.
Publicado: (2022)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors
por: Grad, Robert N, et al.
Publicado: (2023)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis
por: Yarza, Ramon, et al.
Publicado: (2023)

Patterns of Metastasis in Merkel Cell Carcinoma
por: Song, Yun, et al.
Publicado: (2020)

Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
por: Esposito, Andrew, et al.
Publicado: (2021)

Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta‐analysis of individualized participant data
por: Ørholt, Mathias, et al.
Publicado: (2022)

Synovial sarcomas: A single surgeon experience of 130 cases
por: Andreani, Lorenzo, et al.
Publicado: (2022)

Intralesional margin after excision of a high‐grade osteosarcoma: Is it a catastrophe?
por: Tsagkozis, Panagiotis, et al.
Publicado: (2022)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma
por: Marsh, Katherine M., et al.
Publicado: (2022)

Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
por: Huis in ’t Veld, Eva A., et al.
Publicado: (2023)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

Individualized Surgery: Gamma-Probe-Guided Lymphadenectomy in Patients with Clinically Enlarged Lymph Node Metastases from Melanomas
por: Kretschmer, Lutz, et al.
Publicado: (2013)

A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
por: Tripathi, Raghav, et al.
Publicado: (2023)

RE: A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
por: Prieto, Peter A., et al.
Publicado: (2023)

Low-cost optical scanner and 3-dimensional printing technology to create lead shielding for radiation therapy of facial skin cancer: First clinical case series
por: Sharma, Ankur, et al.
Publicado: (2018)

Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy
por: Haywood, Sophia, et al.
Publicado: (2020)

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year
por: Damude, Samantha, et al.
Publicado: (2016)

Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
por: Sondak, Vernon K., et al.
Publicado: (2012)

The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years
por: Deckers, Eric A., et al.
Publicado: (2019)

Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus
por: Nanes, Benjamin A, et al.
Publicado: (2020)

Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China
por: Jin, Hui, et al.
Publicado: (2023)

Merkel Cell Polyomavirus and Merkel Cell Carcinoma
por: Pietropaolo, Valeria, et al.
Publicado: (2020)

DETECTing Merkel Cell Polyomavirus in Merkel Tumors
por: Arora, Reety, et al.
Publicado: (2020)

Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis
por: Cowey, Charles Lance, et al.
Publicado: (2021)

Merkel Cell Polyomavirus and Merkel Cell Carcinoma, France
por: Foulongne, Vincent, et al.
Publicado: (2008)

Merkel cell polyomavirus and cutaneous Merkel cell carcinoma
por: Minutilli, Ettore, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4r32v0aite8v5nau4b946c5l3m